Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
1 other identifier
interventional
40
1 country
1
Brief Summary
The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2019
CompletedFirst Posted
Study publicly available on registry
November 22, 2019
CompletedStudy Start
First participant enrolled
December 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedAugust 26, 2020
August 1, 2020
2 years
November 18, 2019
August 22, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Rate of glucose metabolism
data from fludeoxyglucose positron emission tomography
6 month
Study Arms (2)
Olmesartan group
EXPERIMENTALolmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
Valsartan group
ACTIVE COMPARATORvalsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
Interventions
Eligibility Criteria
You may qualify if:
- dilated cardiomyopathy
You may not qualify if:
- contraindication to angiotensin receptor blocker
- cardiogenic shock
- sensitive to rosuvastatin
- liver cirrhosis more than Child class B
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Internal Medicine,Dong-A University College of Medicine
Busan, South Korea
Related Publications (2)
Jo S, Park K, Choi JH, Sohn CB, Kim J, Kwon YS, Kim SH, Park TH. A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial. J Am Heart Assoc. 2025 Jul;14(13):e041406. doi: 10.1161/JAHA.125.041406. Epub 2025 Jun 27.
PMID: 40576039DERIVEDJo S, Moon H, Park K, Sohn CB, Kim J, Kwon YS, Kim SH. Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials. 2022 Jan 15;23(1):36. doi: 10.1186/s13063-021-05970-7.
PMID: 35033178DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kyungil PARK
Dong-A University Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
November 18, 2019
First Posted
November 22, 2019
Study Start
December 1, 2019
Primary Completion
December 1, 2021
Study Completion
December 31, 2021
Last Updated
August 26, 2020
Record last verified: 2020-08
Data Sharing
- IPD Sharing
- Will not share
We don't have any plan to make individual participant data (IPD) available to other researchers